Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Modern treatment of lung cancer: case 2. Response to erlotinib after failure of gefitinib in a patient with advanced non-small-cell lung carcinoma.

× No keyword cloud information.

11 in total

1. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.

Authors: Daniel B Costa; Kim-Son H Nguyen; Byoung C Cho; Lecia V Sequist; David M Jackman; Gregory J Riely; Beow Y Yeap; Balázs Halmos; Joo H Kim; Pasi A Jänne; Mark S Huberman; William Pao; Daniel G Tenen; Susumu Kobayashi
Journal: Clin Cancer Res Date: 2008-11-01 Impact factor: 12.531

2. T790M and acquired resistance of EGFR TKI: a literature review of clinical reports.

Authors: Chunyan Ma; Shuzhen Wei; Yong Song
Journal: J Thorac Dis Date: 2011-03 Impact factor: 2.895

Review 3. Erlotinib usage after prior treatment with gefitinib in advanced non-small cell lung cancer: A clinical perspective and review of published literature.

Authors: Navneet Singh; Aditya Jindal; Digambar Behera
Journal: World J Clin Oncol Date: 2014-12-10

4. Antitumor activity of a novel EGFR tyrosine kinase inhibitor against human lung carcinoma in vitro and in vivo.

Authors: Xishan Xiong; Lili Fu; Li Wang; Houan Cai; Lin Li; Hualiang Jiang; Wenhu Duan; Changlin Mei
Journal: Invest New Drugs Date: 2008-05-21 Impact factor: 3.850

5. Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment.

Authors: D H Lee; S-W Kim; C Suh; D H Yoon; E J Yi; J-S Lee
Journal: Ann Oncol Date: 2008-07-21 Impact factor: 32.976

6. Sequential responses of adenocarcinoma of the lung to erlotinib after gefitinib in never smoker Korean woman.

Authors: Hoon-Kyo Kim; Myeong Im Ahn; Jinyoung Yoo; Chi Hong Kim; Hong-Jun Yang; Byoung Yong Shim
Journal: Cancer Res Treat Date: 2007-03-31 Impact factor: 4.679

7. Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis.

Authors: Satoshi Watanabe; Junta Tanaka; Takeshi Ota; Rie Kondo; Hiroshi Tanaka; Hiroshi Kagamu; Kosuke Ichikawa; Jun Koshio; Junko Baba; Takao Miyabayashi; Ichiei Narita; Hirohisa Yoshizawa
Journal: BMC Cancer Date: 2011-01-01 Impact factor: 4.430

8. Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer.

Authors: Matthew K Wong; Alvis I Lo; Bing Lam; W K Lam; Mary S Ip; James C Ho
Journal: Cancer Chemother Pharmacol Date: 2009-08-13 Impact factor: 3.333

9. Recovery from paraplegia with administration of erlotinib in a patient with lung adenocarcinoma.

Authors: Koichi Kurishima; Katsunori Kagohashi; Takeo Mammoto; Hiroaki Satoh
Journal: Contemp Oncol (Pozn) Date: 2014-06-03

10. Poorer prognosis in Taiwanese female ever smokers with stage IV lung adenocarcinoma who were readministered a tyrosine kinase inhibitor.

Authors: Chih-Jen Yang; Ming-Ju Tsai; Jen-Yu Hung; Ying-Ming Tsai; Jui-Ying Lee; Shah-Hwa Chou; Ta-Chih Liu; Mei-Chiou Shen; Ming-Shyan Huang; Inn-Wen Chong
Journal: Onco Targets Ther Date: 2016-03-15 Impact factor: 4.147